Aiforia Technologies Plc received a contract award to provide artificial intelligence solutions for 25 NHS Trusts pathology departments in the UK to support the diagnosis of patients. The Contract Award enables the Trusts to purchase directly from Aiforia and to sign individual contracts without worksome tender processes. The technology of the awarded vendor has already been qualified for clinical use, and the contract terms have been set.

PathLAKE drives AI innovation in pathology for the UK intending to leverage the full value of NHS pathology data to drive economic growth in health-related AI. This was the first Call for Competition of its kind within the PathLAKE Plus consortium. In the call for competition related to lung cancer diagnostics solutions, Aiforia was the only supplier who won the contract award for its CE-IVD marked AI model for Lung Cancer, PD-L1.

In the prostate cancer-related call, Aiforia received the contract award as one of the three selected suppliers for its CE-IVD marked AI model for Prostate Gleason Grade Groups. The duration of the individual contracts with the hospitals will be three years, with a possible three-year extension. The estimated volumes mentioned in the tender were 12888 cases annually (109166 slides) for prostate, and 2522 cases (28880 slides) annually for lung cancer PD-L1, with these numbers expected to increase annually.